Velesco expands core scientific and quality team

Appoints director of quality and senior pharmaceutical scientist

Contract research organisation Velesco Pharmaceutical Services, which operates from facilities in Plymouth and Kalamazoo, Michigan, US, has added Shirley Smith as director of quality and Yuan Chen as senior pharmaceutical scientist.

Prior to joining Velesco, Smith was quality assurance manager for Richard-Allan Scientific and senior quality assurance manager for Pfizer’s Drug Product and Device Research Group in Kalamazoo, MI.

In conjunction with her role at Velesco, Smith will continue her leadership position at PharmaMed Resources, a quality assurance and regulatory affairs consultancy that services the Medical Device and Pharmaceutical Industries.

Chen has extensive experience in analytical methods development and validation, cleaning verification and validation, and drug release testing.

Before joining Velesco, Chen served in the Pharmaceutical Sciences Division of Pfizer Global R&D as a senior associate scientist for eight years and the Analytical Development Department of Caraco Pharmaceutical Laboratories for two years. Her experience spans the drug development spectrum from early stage development and validation of stability-indicating methods for the release of drug substance and drug product, to later stage projects focused on the detection of residual drugs on manufacturing equipment.

You may also like

Research & Development

Velesco Pharma expands and opens new cGMP-compliant analytical testing laboratory

Increases the breadth of its services to meet client needs
Research & Development

Quotient Sciences and CPI to accelerate RNA drug development with joint venture

The JV will address the growing industry demand for agile solutions that bring new RNA therapeutics to patients with greater speed and confidence
Research & Development

Naobios, Nuvonis and the European Vaccine Initiative collaborate to manufacture influenza challenge agent

Working with the Inno4Vac consortium, Naobios will leverage Nuvonis’s Vero Cell Bank to support the development of a controlled human infection model based on the influenza virus A(H3N2)
Research & Development

Wegovy cuts risk of heart attack, stroke or death by 57% compared with tirzepatide

Study adds to growing evidence suggesting that the heart-protective benefits seen with Wegovy are specific to the semaglutide molecule and therefore cannot be extended to other GLP-1 or GIP/GLP-1-based treatments
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Formulation meets function: addressing palatability in drug development (part I)

Patient adherence to treatment regimens is inextricably linked to the palatability of medications, with consequences that can be far more serious than simply leaving a bad taste in one’s mouth
Research & Development

Hamilton Health Sciences chosen for BirchBioMed burn scar treatment trial

BirchBioMed announces Hamilton Health Sciences’ (HHS) Centre for Burn Research in Ontario as the first contracted clinical trial site for its Phase II/III randomised study of the naturally based compound: FS2.
Research & Development

Indena and TCG GreenChem join forces to advance next-generation ADC technologies

Indena and TCG GreenChem are pleased to announce a new strategic collaboration aimed at accelerating the development of innovative and market-ready payload-linkers: the key component of antibody-drug conjugates (ADCs)
Subscribe now